TABLE 1.
Baseline information for patients in SCIT and medication groups.
| Items | SCIT group |
Medication group |
P Value |
| (n = 35) | (n = 20) | ||
| Gender m/f (cases) | 25/10 | 12/8 | >0.05 |
| Age distribution (y) | 20.3 ± 2.2 | 22.3 ± 2.5 | >0.05 |
| Children (≤14) | 15 (9.1 ± 0.5) | 6 (8 ± 0.6) | >0.05 |
| Adults (>14) | 20 (28.8 ± 2.6) | 14 (30 ± 1.9) | >0.05 |
| Case distribution cases (%) | |||
| Asthma | 5 (14.3) | 2 (10.0) | >0.05 |
| Rhinitis | 4 (11.4) | 3 (15.0) | >0.05 |
| Asthma combined | 26 (74.3) | 15 (75.0) | >0.05 |
| Rhinitis | |||
| Symptom and medication | 3.67 ± 0.42 | 3.82 ± 0.45 | >0.05 |
| score | |||
| FEV1 (%predicted) | 91.16 ± 2.25 | 91.64 ± 1.81 | >0.05 |
| FVC (%predicted) | 98.05 ± 1.50 | 93.85 ± 2.17 | >0.05 |
| Total IgE (kU/1) | 477 ± 65 | 562 ± 47 | >0.05 |
| Specific IgE to Der p (kU/1) | 85 ± 11 | 87 ± 11 | >0.05 |
Data are presented as mean ± SE. FEV1, forced expiratory volume at 1s; FVC, forced vital capacity; IgE, immunoglobulin E.